Cognition Therapeutics, Inc. (NASDAQ:CGTX) Given Consensus Rating of “Moderate Buy” by Analysts

Cognition Therapeutics, Inc. (NASDAQ:CGTX) has earned an average rating of “Moderate Buy” from the four research firms that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation and three have given a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $3.3333.

A number of equities analysts have issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cognition Therapeutics in a research note on Wednesday, June 24th. HC Wainwright restated a “buy” rating on shares of Cognition Therapeutics in a research report on Thursday, August 13th. Finally, Wall Street Zen lowered shares of Cognition Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th.

Hedge Funds Weigh In On Cognition Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Sigma Planning Corp raised its holdings in Cognition Therapeutics by 7.3% during the 2nd quarter. Sigma Planning Corp now owns 362,265 shares of the company’s stock worth $417,000 after buying an additional 24,500 shares during the period. Corient Private Wealth LP acquired a new position in shares of Cognition Therapeutics in the second quarter valued at approximately $93,000. Tocqueville Asset Management L.P. acquired a new position in Cognition Therapeutics in the 2nd quarter worth $369,000. Texas Capital Bank Wealth Management Services Inc acquired a new stake in shares of Cognition Therapeutics in the 2nd quarter valued at about $165,000. Finally, BlackRock Inc. acquired a new stake in shares of Cognition Therapeutics in the 2nd quarter valued at about $1,451,000. 43.35% of the stock is currently owned by institutional investors and hedge funds.

Cognition Therapeutics Stock Performance

NASDAQ:CGTX traded up $0.01 on Friday, hitting $1.06. 41,360 shares of the stock were exchanged, compared to its average volume of 1,075,277. The stock has a market capitalization of $101.28 million, a price-to-earnings ratio of -6.26 and a beta of 1.79. Cognition Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.05. The company’s 50-day moving average price is $1.00 and its 200 day moving average price is $1.09.

Cognition Therapeutics (NASDAQ:CGTX) last issued its earnings results on Thursday, August 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.02. As a group, equities research analysts predict that Cognition Therapeutics will post -0.3 earnings per share for the current year.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines for neurodegenerative diseases. The company’s research centers on the sigma-2 receptor, also known as SIGMAR2, a protein believed to play a role in the cellular processes associated with cognitive decline and neurodegeneration.

Cognition Therapeutics’ lead product candidate is CT1812, an orally administered, brain-penetrant small molecule designed to modulate SIGMAR2. The investigational therapy is being evaluated for Alzheimer’s disease and other forms of dementia, including dementia with Lewy bodies.